Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peripheral T-cell Lymphomas (PTCL)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02404571
What this trial is testing

GDP in Frontline Chemotherapy for Patients With PTCL-NOS

Who this might be right for
Lymphoma, T-Cell, Peripheral
Chinese Academy of Medical Sciences 28
Testing effectiveness (Phase 2)WithdrawnNCT06692452
What this trial is testing

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Who this might be right for
LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell Lymphoma+2 more
Eric Jacobsen, MD
Early research (Phase 1)Ended earlyNCT04548700
What this trial is testing

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

Who this might be right for
Treatment-naïvePeripheral T Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07347288
What this trial is testing

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

Who this might be right for
PTCL
The First Affiliated Hospital with Nanjing Medical University 30
Early research (Phase 1)Study completedNCT02809573
What this trial is testing

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Who this might be right for
Peripheral T-cell Lymphoma
Chipscreen Biosciences, Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT02953652
What this trial is testing

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL)
HUYABIO International, LLC. 55
Testing effectiveness (Phase 2)UnknownNCT05238064
What this trial is testing

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Who this might be right for
PI3Kδ InhibitorParsaclisibCHOP+1 more
Fudan University 30
Testing effectiveness (Phase 2)UnknownNCT02495415
What this trial is testing

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphoma
CerRx, Inc. 140
Not applicableUnknownNCT06509945
What this trial is testing

Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

Who this might be right for
Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 50
Testing effectiveness (Phase 2)Study completedNCT00481871
What this trial is testing

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Who this might be right for
Relapsed or Refractory Lymphoproliferative MalignanciesHodgkin's LymphomaPeripheral T-cell Lymphoma+2 more
Acrotech Biopharma Inc. 119
Testing effectiveness (Phase 2)Study completedNCT04569032
What this trial is testing

Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Who this might be right for
Peripheral T-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 82
Testing effectiveness (Phase 2)UnknownNCT05559008
What this trial is testing

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Who this might be right for
Peripheral T Cell Lymphoma
Ruijin Hospital 116
Testing effectiveness (Phase 2)Active Not RecruitingNCT04984837
What this trial is testing

Study of Lacutamab in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapse/Recurrence
The Lymphoma Academic Research Organisation 49
Large-scale testing (Phase 3)UnknownNCT05822050
What this trial is testing

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

Who this might be right for
PTCL Patients Who Achieved Complete Response From Frontline Treatment
The First Hospital of Jilin University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07676175
What this trial is testing

BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)

Who this might be right for
Previously Untreated Peripheral T-Cell Lymphoma
BeBetter Med Inc 120
Testing effectiveness (Phase 2)UnknownNCT03502629
What this trial is testing

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Who this might be right for
Peripheral T Cell Lymphoma
Genor Biopharma Co., Ltd. 86
Testing effectiveness (Phase 2)Study completedNCT05140382
What this trial is testing

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Who this might be right for
Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Classical Hodgkins Lymphoma
AstraZeneca 52
Testing effectiveness (Phase 2)Study completedNCT00791947
What this trial is testing

A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

Who this might be right for
Peripheral T-Cell Lymphoma
University of Aarhus 166
Not applicableLooking for participantsNCT07074457
What this trial is testing

Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

Who this might be right for
CD30+ Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University 47
Not applicableUnknownNCT03672084
What this trial is testing

Allo-HSCT as First-line Consolidation in High-risk PTCL

Who this might be right for
T Cell Lymphoma
Peking University People's Hospital 50
Next Page